Triple
T23186578
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | George D. Yancopoulos |
E579607
|
entity |
| Predicate | notableWork |
P4
|
FINISHED |
| Object | Regeneron’s VelociGene platform |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Regeneron’s VelociGene platform | Statement: [George D. Yancopoulos, notableWork, Regeneron’s VelociGene platform]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Regeneron’s VelociGene platform Context triple: [George D. Yancopoulos, notableWork, Regeneron’s VelociGene platform]
-
A.
VelocImmune technology
VelocImmune technology is Regeneron’s proprietary platform that uses genetically engineered mice to rapidly produce fully human monoclonal antibodies for therapeutic development.
-
B.
VelociGene
chosen
VelociGene is a high-throughput genetic engineering platform developed by Regeneron to precisely modify mouse and human genes for functional genomics and drug discovery research.
-
C.
HyperAcute cellular immunotherapy platform
HyperAcute cellular immunotherapy platform is a cancer treatment technology that uses genetically modified tumor cells to stimulate a strong immune response against cancer.
-
D.
REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e245ff8000819090d12008805315b7 |
completed | April 17, 2026, 2:38 p.m. |
| NER | Named-entity recognition | batch_69f18fd3aaa08190b9cf7afe4ee5a38d |
completed | April 29, 2026, 4:57 a.m. |
Created at: April 17, 2026, 4:05 p.m.